Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HIV/AIDS

Not applicable

Mouse studies suggest a combination of neutralizing antibodies could help treat HIV. In a humanized mouse model of HIV, individual antibodies with high in vitro potency against various HIV epitopes decreased viral RNA compared with no treatment but led to viremia rebound after 14-16 days. In the mouse model, a combination of five such antibodies against different binding sites, including CD4 and different HIV epitopes, suppressed HIV viral load for up to 60 days after discontinuing therapy, whereas antiretroviral therapies suppressed viral load for 10 days after discontinuing therapy. Next steps include clinical trials.

SciBX 5(45); doi:10.1038/scibx.2012.1184
Published online Nov. 15, 2012

Patent applications filed covering three of the antibodies; available for licensing

Klein, F. et al. Nature; published online Oct. 24, 2012;
doi:10.1038/nature11604
Contact: Michel C. Nussenzweig, The Rockefeller University,
New York, N.Y.
e-mail:

nussen@rockefeller.edu